Prostate Cancer Daily

June 12, 2026

Videos

Peer-to-Peer Clinical Conversations

Real-World Testosterone Recovery After Relugolix: Interim Results from the OPTYX Registry - Benjamin Lowentritt

Benjamin Lowentritt

Benjamin Lowentritt presents an interim analysis from the OPTYX phase 4 registry.

View

Real-World Overall Survival with Apalutamide Versus Abiraterone in mHSPC - Benjamin Lowentritt

Benjamin Lowentritt

Neeraj Agarwal hosts Benjamin Lowentritt to discuss a real-world evidence study comparing apalutamide versus abiraterone in metastatic hormone-sensitive prostate cancer.

View

Beyond the Abstracts

Therapeutic Targeting of Prostate-Specific Membrane Antigen Could Limit Its Potential as Benchmark Imaging - Beyond the Abstract

Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [18F]PSMA-1007 PET/CT and [18F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management - Beyond the Abstract

Conference Coverage

SNMMI 2026: Baseline PSMA PET Tumor Volume Predicts Overall Survival with 177Lu-PSMA-I&T in Individual mCRPC patients: A Single-Center Real-World Study

ASCO 2026: Assessing the Clinical and Biological Associations Between MMAI and 22-Gene GC in Localized Prostate Cancer

ASCO 2026: Rad2Nivo: Phase Ib Study of Radium-223 with Nivolumab in Patients with mCRPC

AUA 2026: IRRADIANT: Irreversible Electroporation versus Radiation Boost for Intermediate Risk Prostate Cancer

AUA 2026: AMPLIFY: A Phase 3 Study of 64Cu-SAR-bisPSMA Positron Emission Tomography in Participants with Biochemical Recurrence of Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Cell-free DNA in prostate cancer and treatment selection.

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login